NDC 71335-1290

Acyclovir

Acyclovir

Acyclovir is a Oral Capsule in the Human Prescription Drug category. It is labeled and distributed by Bryant Ranch Prepack. The primary component is Acyclovir.

Product ID71335-1290_0f4edbc4-9632-4f58-a049-aef87d2cc1b4
NDC71335-1290
Product TypeHuman Prescription Drug
Proprietary NameAcyclovir
Generic NameAcyclovir
Dosage FormCapsule
Route of AdministrationORAL
Marketing Start Date2017-08-17
Marketing CategoryANDA / ANDA
Application NumberANDA206261
Labeler NameBryant Ranch Prepack
Substance NameACYCLOVIR
Active Ingredient Strength200 mg/1
Pharm ClassesDNA Polymerase Inhibitors [MoA],Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC],Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC],Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor [EPC],Nucleoside Analog [EXT]
NDC Exclude FlagN
Listing Certified Through2020-12-31

Packaging

NDC 71335-1290-0

90 CAPSULE in 1 BOTTLE (71335-1290-0)
Marketing Start Date2022-02-23
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 71335-1290-4 [71335129004]

Acyclovir CAPSULE
Marketing CategoryANDA
Application NumberANDA206261
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-01-01
Marketing End Date2020-02-29

NDC 71335-1290-6 [71335129006]

Acyclovir CAPSULE
Marketing CategoryANDA
Application NumberANDA206261
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-01-01
Marketing End Date2020-02-29

NDC 71335-1290-5 [71335129005]

Acyclovir CAPSULE
Marketing CategoryANDA
Application NumberANDA206261
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-01-01
Marketing End Date2020-02-29

NDC 71335-1290-1 [71335129001]

Acyclovir CAPSULE
Marketing CategoryANDA
Application NumberANDA206261
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-01-01
Marketing End Date2020-02-29

NDC 71335-1290-8 [71335129008]

Acyclovir CAPSULE
Marketing CategoryANDA
Application NumberANDA206261
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-01-01
Marketing End Date2020-02-29

NDC 71335-1290-7 [71335129007]

Acyclovir CAPSULE
Marketing CategoryANDA
Application NumberANDA206261
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-01-01
Marketing End Date2020-02-29

NDC 71335-1290-0 [71335129000]

Acyclovir CAPSULE
Marketing CategoryANDA
Application NumberANDA206261
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-01-01
Marketing End Date2020-02-29

NDC 71335-1290-3 [71335129003]

Acyclovir CAPSULE
Marketing CategoryANDA
Application NumberANDA206261
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-01-01
Marketing End Date2020-02-29

NDC 71335-1290-2 [71335129002]

Acyclovir CAPSULE
Marketing CategoryANDA
Application NumberANDA206261
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-01-01
Marketing End Date2020-02-29

NDC 71335-1290-9 [71335129009]

Acyclovir CAPSULE
Marketing CategoryANDA
Application NumberANDA206261
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-01-01
Marketing End Date2020-02-29

Drug Details

Active Ingredients

IngredientStrength
ACYCLOVIR200 mg/1

OpenFDA Data

SPL SET ID:01ae85df-d1a0-44f7-b4c0-0ac74d2216d4
Manufacturer
UNII
RxNorm Concept Unique ID - RxCUI
  • 197310

    • Pharmacological Class

    • DNA Polymerase Inhibitors [MoA]
    • Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC]
    • Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC]
    • Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor [EPC]
    • Nucleoside Analog [EXT]
    • DNA Polymerase Inhibitors [MoA]
    • Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC]
    • Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC]
    • Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor [EPC]
    • Nucleoside Analog [EXT]

    NDC Crossover Matching brand name "Acyclovir" or generic name "Acyclovir"

    NDCBrand NameGeneric Name
    0093-3630Acycloviracyclovir
    0093-8940AcyclovirAcyclovir
    0093-8943AcyclovirAcyclovir
    0093-8947AcyclovirAcyclovir
    0143-9657AcyclovirAcyclovir
    0143-9658AcyclovirAcyclovir
    0168-0825acycloviracyclovir
    0378-8700Acycloviracyclovir
    0378-8712AcyclovirAcyclovir
    0440-6030AcyclovirAcyclovir
    0440-7033acycloviracyclovir
    0472-0082AcyclovirAcyclovir
    0591-1159Acycloviracyclovir
    0713-0630AcyclovirAcyclovir
    0904-5789ACYCLOVIRACYCLOVIR
    0904-5790acycloviracyclovir
    10544-039Acycloviracyclovir
    10544-089Acycloviracyclovir
    10544-101AcyclovirAcyclovir
    68071-1841AcyclovirAcyclovir
    68071-3155AcyclovirAcyclovir
    68071-3222AcyclovirAcyclovir
    68071-4528AcyclovirAcyclovir
    68071-4559acycloviracyclovir
    68071-4345AcyclovirAcyclovir
    68084-109AcyclovirAcyclovir
    68084-108AcyclovirAcyclovir
    68071-4790AcyclovirAcyclovir
    68071-4799AcyclovirAcyclovir
    68084-107ACYCLOVIRACYCLOVIR
    68382-125acycloviracyclovir
    68382-049acycloviracyclovir
    68382-048acycloviracyclovir
    68382-668acycloviracyclovir
    68382-126acycloviracyclovir
    68382-792acycloviracyclovir
    68382-791acycloviracyclovir
    68382-992acycloviracyclovir
    68462-746acycloviracyclovir
    68788-6360acycloviracyclovir
    68788-0505AcyclovirAcyclovir
    68788-0504AcyclovirAcyclovir
    68788-0715AcyclovirAcyclovir
    68788-8989acycloviracyclovir
    68788-6827ACYCLOVIRACYCLOVIR
    68788-7382acycloviracyclovir
    68788-7378acycloviracyclovir
    68788-9783AcyclovirAcyclovir
    68788-7342AcyclovirAcyclovir
    68788-9690AcyclovirAcyclovir
    © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.